Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging

Lipid nanoparticles (LNPs) have been one of the most successful nano-delivery vehicles that enable efficient delivery of cytotoxic chemotherapy agents, antibiotics, and nucleic acid therapeutics. During the coronavirus disease (COVID-19) pandemic, LNP-based COVID-19 messenger RNA (mRNA) vaccines from Pfizer/BioNTech and Moderna have been successfully developed, resulting in global sales of $37 billion and $17.7 billion, respectively, in 2021. Based on this success, the development of multiple LNP-based RNA therapeutics is gaining momentum due to its potential in vaccines and therapeutics for various genetic diseases and cancers. Furthermore, imaging techniques can be utilized to evaluate the pharmacokinetics…

• NR
  National Research Foundation

  Award: 2020R1A2C2011695
• SN
  Seoul National University
• MO
  Ministry of Trade, Industry and Energy

  Award: 20018522
• MO
  Ministry of Food and Drug Safety

  Award: 22213MFDS421
• NR
  National Research Foundation of Korea

  Awards: NRF-2020R1A2C2011695, 2019M2D2A1A01058210, NRF-2019M2D2A1A01058210, 2021M2E8A1039564, 20018522, 2020R1A2C2011695
• MO
  Ministry of Science and ICT, South Korea

  Award: NRF-2019M2D2A1A01058210
• KE
  Korea Evaluation Institute of Industrial Technology

  Awards: No. 20018522, 20018522